August 12, 2022
Doyle's Guide

DibbsBarker adds two laterals to partnership

DibbsBarker has announced the lateral appointment of Melissa McGrath and Jamie Palmer to the firm’s partnership.

McGrath returns to the firm after a stint with Ashurst. Her move continues the growth of DibbsBarker’s intellectual property litigation practice, particularly in the area of patent litigation.

McGrath’s practice covers all aspects of intellectual property, including the protection of confidential information, with a focus on patent and trade mark litigation and particularly practised in pharmaceutical patent litigation,
having acted for both generic and originator companies on various patent-related disputes.

Jamie Palmer adds depth to DibbsBarker’s private equity practice. He
brings knowledge and experience from undertaking transactional work for some of the leading private equity firms and both national and multinational corporates in Australia while at Allen & Overy and, prior to that, at Freehills.

DibbsBarker Managing Partner, Alan McArthur, said “The firm is delighted to welcome Melissa and Jamie to the partnership. Their appointments demonstrate continuing growth and capability in our chosen industries and areas of practice at a time when the legal services market is contracting. We continue to see significant opportunities in working with our clients in the life sciences, technology and private equity areas.”

“Melissa and Jamie, along with the two partner promotions we announced last month, represent a new generation of talented business owners who are growing market share and profile in a very restrained environment. Their energy and fresh ideas, backed by a team of over 300, continues the evolution of the firm as we build a fully integrated east coast service capability.”

McGrath and Palmer joined the firm in August and both of them are based in the DibbsBarker Sydney office.

Share this page...
Follow by Email
Facebook
Twitter
LinkedIn
Share

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More